Knights of Columbus Asset Advisors LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Knights of Columbus Asset Advisors LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 420.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 153,949 shares of the company’s stock after purchasing an additional 124,396 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.29% of Viridian Therapeutics worth $3,353,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Metropolitan Life Insurance Co NY grew its position in shares of Viridian Therapeutics by 47.0% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,340 shares of the company’s stock valued at $68,000 after purchasing an additional 748 shares in the last quarter. Royal Bank of Canada lifted its holdings in Viridian Therapeutics by 48.8% in the second quarter. Royal Bank of Canada now owns 3,199 shares of the company’s stock valued at $76,000 after acquiring an additional 1,049 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Viridian Therapeutics by 1,874.2% in the first quarter. Tower Research Capital LLC TRC now owns 3,218 shares of the company’s stock worth $82,000 after acquiring an additional 3,055 shares during the period. Silverarc Capital Management LLC purchased a new position in Viridian Therapeutics in the fourth quarter worth approximately $88,000. Finally, Legal & General Group Plc purchased a new position in Viridian Therapeutics in the second quarter worth approximately $94,000.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. B. Riley lowered their price objective on Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Wedbush increased their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $36.60.

Insider Activity at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc bought 476,190 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The stock was purchased at an average cost of $21.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director now owns 1,839,954 shares in the company, valued at approximately $38,639,034. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.43% of the stock is currently owned by company insiders.

Viridian Therapeutics Stock Down 3.7 %

VRDN opened at $14.60 on Friday. Viridian Therapeutics, Inc. has a 52 week low of $10.93 and a 52 week high of $30.30. The business has a fifty day simple moving average of $17.70 and a 200-day simple moving average of $17.53. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.26 and a current ratio of 18.26.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.37). The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The company’s revenue for the quarter was down 31.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.13) earnings per share. On average, equities analysts predict that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.